Reendothelialization in the aneurysm neck is pivotal to vascular repair for intracranial aneurysm after flow diverter (FD) implantation. Recombinant human stromal cell-derived factor 1α (rhSDF-1α) is a vital chemoattractant to stem cells and potentially facilitates reendothelialization. Here, we sought to investigate the therapeutic effects of intravenous administration of rhSDF-1α and uncover its potential mechanism for promoting aneurysm neck reendothelialization. Recombinant pET32a-186 plasmid was transformed into Escherichia coli to produce the rhSDF-1α protein with biological activity. FD was implanted into the elastase-induced saccular aneurysm in New Zealand white rabbits. rhSDF-1α (50 μg/kg/day) was intravenously administrated for consecutive 7 days after FD implantation. After these procedures, aneurysms were harvested after 2 or 4 weeks. Scanning electron microscopy was used to measure the neointima thickness and count the endothelial-like cells at aneurysm neck. Four weeks later, the mRNA levels of endothelial markers in the neointima at aneurysm neck were examined. Migration assay showed that rhSDF-1α could induce migration of endothelial progenitor cells in a dose-dependent manner. Two weeks after stent implantation, follow-up angiography showed partial aneurysm occlusion in one of each group and total aneurysm occlusion in 17 saccular aneurysm rabbits (9 of the rhSDF-1α group and 8 of the control group). No significant change of neointima thickness at aneurysm neck was observed. Intriguingly, more endothelial-like cells were observed at aneurysm neck in the rhSDF-1α group at 2 weeks (55 vs 13 cells per high-power field) and 4 weeks (104 vs 60 cells per high-power field). The mRNA levels of Tie-2, VE-cadherin, KDR and E-selectin were significantly enhanced compared with those of the control group. These results showed that intravenous administration of rhSDF-1α can accelerate reendothelialization in the aneurysm neck after FD implantation. Our study reveals an important role of rhSDF-1α in inducing aneurysm occlusion and suggests that it achieves its function through modulating the reendothelialization.
Introduction
Intracranial aneurysm is a common condition and often asymptomatic until rupture. Flow diverter (FD) devices are widely used to treat intracranial aneurysms by reconstructing the parent artery to facilitate aneurysm occlusion [1, 2] . However, this strategy encountered many challenges such as thromboembolism and perforator occlusion [3] . After FD treatment, antiplatelet therapy containing high-dose aspirin is usually used to prevent in-stent thrombosis. Applying high-dose aspirin often leads to hemorrhage, whereas low-dose aspirin tends to ischemia [4] . With dual antiplatelet therapy, the follow-up ischemic complications often occur one year after FD implantation [1, 2, 5, 6] . The undesired side-effects are most commonly associated with incomplete reendothelialization. Therefore, accelerating the reendothelialization after FD implantation is critical to reduce the risk of ischemia or hemorrhage.
We previously used autologous self-expanded bone marrow (BM)-derived endothelial progenitor cells (EPCs) to accelerate reendothelialization at aneurysm neck after FD treatment [7] . However, culture and expansion of autologous EPCs are quite complicated and time-consuming. Moreover, this strategy has the risk of cell contamination. Recently, accumulating evidence showed that EPCs, smooth muscle progenitor cells, and other stem cells are involved in tissue repair [8, 9] . Therefore, application of chemokines attracting or mobilizing self-derived stem cells is potentially a more efficient approach for promoting reendothelialization.
Stromal cell-derived factor 1 (SDF-1), which is released by endothelial and smooth muscle cells as well as other resident cells in response to injury, is a vital chemoattractant to stem cells [10] [11] [12] . It has been reported that SDF-1 plays an important role in stem cell recruitment and homing to injured tissue [13] by coupling with its ligand CXCR4 expressed in stem cells. Hoh et al. [14] reported that SDF-1 is associated with angiogenesis. Moreover, SDF-1 promotes inflammatory cell migration and proliferation in the walls of aneurysms. SDF-1 also promotes endothelial cell and macrophage migration. Zernecke et al. [15] showed that elevated SDF-1α expression in injured tissue can promote vascular remodeling via recruiting smooth muscle progenitor cells. Noels et al. [16] demonstrated that CXCR4 is essential for reendothelialization after vascular injury through mobilization of circulating EPCs via SDF-1/CXCR4 axis. Zhang et al. [17] used recombinant human SDF-1α (rhSDF-1α) to facilitate reendothelialization after drug-eluting stent implantation in aorta abdominalis. All these evidence suggests that applying SDF-1 is an attractive strategy for reendothelialization and neointima formation after vascular injury. However, whether rhSDF-1α plays a critical role in aneurysm neck reendothelialization after FD implantation remains elusive.
In this study, we aimed to explore the potential application of rhSDF-1α to accelerate neointima reendothelialization in elastaseinduced saccular aneurysm. We demonstrated that intravenous administration of rhSDF-1α could accelerate reendothelialization in aneurysm neck after FD implantation in elastase-induced saccular aneurysm rabbits. Our study reveals that rhSDF-1α plays an important role in facilitating aneurysm occlusion through modulating the reendothelialization.
Materials and Methods

Animal models of saccular aneurysm
The entire study was carried out in strict accordance with protocols approved by the Chinese Convention on Use of Laboratory Animals. The protocols were approved by Shanghai Second Military University Ethics Committee. All surgical procedures were performed under combined anesthesia with 1% sodium pentobarbital (intravenous, 1 ml/kg) and xylazine (intramuscular, 0.1 mg/kg). All efforts were made to minimize suffering. Each animal was caged with free access to water and food. Animals were sacrificed with overdosed sodium pentobarbital.
Twenty New Zealand white male rabbits (range: 2.7-3.5 kg) were purchased from the laboratory animal center of Shanghai Second Military Medical University. The rabbits were randomly divided into two groups (control group and rhSDF-1α group). The rabbits were anesthetized with 1% sodium pentobarbital (intravenous, 1 ml/kg) and xylazine (intramuscular, 0.1 mg/kg). After the right common carotid artery was exposed, the origin and partial wall of the subclavian artery were clipped with a temporary arcuate aneurysm clip, and 2-cm proximal to the origin of right common carotid artery was ligated. The stump was punctured with a 22-gauge catheter, and the inner lumen of the proximal portion was incubated for~20 min with 75 U of porcine pancreatic elastase (Sigma-Aldrich, St Louis, USA) via catheter. The aneurysm clip was removed after ligation of the catheter puncture point. After models were established, rabbits were caged with adequate water and food. The above saccular aneurysm rabbit models were established using protocol described previously [7] .
FD implantation
Three weeks after the model establishment, FDs (Tubridge; Microport, Shanghai, China) braided with 40% metal coverage were implanted into saccular aneurysm. Prior to the procedure, dual antiplatelet regimen (aspirin, 15 mg/kg/day; clopidogrel, 15 mg/kg/day) was given by gavage for 5 days. After stent implantation, dual antiplatelet regimen was continued until tissue harvest. The procedure was performed under digital subtraction angiography (WINMEDIC2000; Lepu Medical, Beijing, China) after anesthesia. Access was obtained in the surgically exposed common iliac artery after insertion of a 5 French (Fr) sheath (Terumo, Tokyo, Japan). Angiography with an Envoy 5 Fr guiding catheter (Cordis Corporation, Miami, USA) was performed to evaluate the aneurysm morphology after general heparinization with a dose of 300 IU/kg. FD with two diameters of 3.5 and 4.0 mm was used based on the subclavian artery diameters. The FD was delivered via Vasco microcatheter (Balt, Montmorency, France) and fully covered the aneurysm neck. Angiography was used to evaluate the stent location and immediate result. When the procedure was finished, penicillin (400,000 U) was injected to prevent postoperative infection.
rhSDF-1α synthesis and purification
Human SDF-1α gene was cloned into the expression vector pET32a (Novagen, Madison, USA) at BamHI/XhoI sites (ChinaPeptides Corporation, Shanghai, China). The recombinant plasmids were transformed into Escherichia coli BL21(DE3). Transformed E. coli cells were cultured in Luria-Bertani culture medium at 37°C for 3 h and induced with isopropylthiogalactoside (IPTG) at 28°C for 3 h. rhSDF-1α protein expression was analyzed with 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The soluble fusion protein was purified using affinity chromatography with His-tag/ Ni-NTA system (Qiagen, Valencia, USA) and eluted with imidazole.
Culture, isolation, and expansion of EPCs
Under general anesthesia, 2 ml fresh BM was obtained by iliac crest aspiration. BM-derived EPCs were isolated with Ficoll gradient centrifugation and plated on 25 cm 2 fibronectin-coated flasks. To expand EPCs, the isolated cells were cultured with endothelial growth medium-2 microvascular (EGM-2 MV; Lonza, Basel, Switzerland) for consecutive 7 days. EPCs were verified according to the staining of CD133, CD34, and vascular endothelial growth factor receptor-2.
The fluorescence emitted by fluorescein isothiocyanate-ulex europaeus agglutinin I (FITC-UEA-I) (Sigma-Aldrich) and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate-labeled AcLDL (DiI-acLDL) (Molecular Probes, Eugene, USA) was observed under a fluorescence microscope (IX70; Olympus, Tokyo, Japan).
Migration assay for biological activity of rhSDF-1α on EPCs
After peptide expression and purification, biological activity was analyzed by migration assay [16] . Boyden chamber (Corning Co., Corning, USA) with 8 μm-pore-size transwell membrane was used. Briefly, EPCs were suspended in EGM-2 MV supplemented 0.5% bovine serum albumin. A total of 1 × 10 4 cells were suspended in 150 μl of EGM-2 MV and placed in the upper compartment. The lower compartment contained the rhSDF-1α protein at different concentrations in a volume of 700 μl. After incubation for 12 h at 37°C with 6% CO 2 , migrated cells were stained with crystal violet after fixation, and countered under a microscope.
Flow cytometry analysis on the EPC percentage in peripheral blood after rhSDF-1α administration rhSDF-1α (50 μg/kg) was intravenously injected into rabbits (n = 8) via ear margin vein. After 0, 4, 8, 12, and 24 h, 0.5 ml of blood samples were collected from the central artery of the ear and analyzed with the FACSCalibur flow cytometer (BD Biosciences, Mountain View, USA), respectively. The FITC-conjugated anti-human KDR (R&D, Minneapolis, USA), APC-conjugated anti-human CD34 (R&D), and PEconjugated CD133 (Miltenyi Biotec, Auburn, USA) were used for the detection of the EPCs. Isotype-matched IgG1 (R&D) was used as control.
rhSDF-1α administration and tissue processing rhSDF-1α (50 μg/kg/day) was intravenously injected into 10 saccular aneurysm rabbits via ear margin vein for consecutive 7 days after FD implantation. The same dose of saline was injected into 10 saccular aneurysm rabbits in the control group. Two and 4 weeks later, saccular aneurysm rabbits were sacrificed with an overdose of sodium pentobarbital. Aneurysm and the parent artery were obtained from these rabbits and then harvested, respectively. For morphological analysis, the left ventricle was first perfused with 200 ml saline containing 4000 U heparin followed by 4% paraformaldehyde before aneurysm harvesting. For RNA analysis, 200 ml saline containing 4000 U heparin was used for perfusion before harvesting. Aneurysm neck together with surrounding endothelial tissue was harvested and dissected in half from implanted parent arteries and stored at -80°C for pooled RNA extraction. The stent struts were drawn with microforceps under an SZ61 microscope (Olympus). Samples were fixed with 4% paraformaldehyde or 2.5% glutaraldehyde for morphological analysis by a scanning electron microscopy (SU-8010; Hitachi, Tokyo, Japan) and hematoxylin-eosin staining.
Examination of expression of endothelial markers at the aneurysm neck
Total RNA was extracted using TRIzol reagent (Invitrogen CA, USA) according to the manufacturer's instructions. Endothelial markers, including CD34, VE-cadherin, Tie-2, KDR, and E-selectin, were amplified by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). The quantitative endpoint for real-time PCR is the threshold cycle (CT). Gene expression was calculated using the relative quantification method with the equation 2
−ΔΔCT
, where ΔΔCT = ΔCT sample -ΔCT control . ΔCT sample = CT target sample − CT reference sample , ΔCT control = CT target control − CT reference control . GAPDH was the reference gene and normal common carotid artery was considered as control.
Observation of endothelial-like cells by scanning electron microscopy
To investigate the reendothelialization process of aneurysm neck, three aneurysms were harvested and fixed with 4% paraformaldehyde at 2 and 4 weeks after FD implantation. Spindle-shaped endothelial-like cells were observed and counted by the scanning electron microscopy.
Statistical analysis
Continuous variables were expressed as the mean ± SD and the differences between two groups were analyzed with Student's t-test. Analysis involved more groups was performed with analysis of variance and a Student-Newman-Keuls post hoc test. P < 0.05 was considered of statistically significant difference.
Results
Establishment of elastase-induced saccular aneurysm rabbit models
To establish mature saccular aneurysm models, saccular aneurysm was induced by elastase and followed up with angiography at 3 weeks. All models were successfully established with aneurysmal dilation at the right common carotid artery stump. Three weeks after model establishment, angiography demonstrated that the aneurysm height, width, and neck reached 7.17 ± 0.45, 5.08 ± 0.23, and 4.55 ± 0.17 mm respectively, while in the control group they reached 7.19 ± 0.47, 5.13 ± 0.25, and 4.49 ± 0.15 mm, respectively. These data indicated that no significant difference between the two groups on the indices of neck, height, and width (P > 0.05).
Recombinant rhSDF-1α induces the migration of EPCs
To examine whether the purified rhSDF-1α has biological activity, migration assay was performed with EPCs which were successfully cultured and verified using the above-mentioned method. The inserted target DNA sequence was 414 bp in length. The target protein expressed from pET32a was mostly soluble. The appropriate concentration of imidazole in eluted buffer was 100 mM. After purification, the recombinant protein was obtained at a concentration of 2 mg/ml. With 0, 10, 100, and 500 ng/ml rhSDF-1α, the number of migrated EPCs in the lower chamber was counted. There were 63 ± 7, 105 ± 10, 155 ± 12, and 310 ± 25 migrated EPCs, respectively. Significant difference was observed between rhSDF-1α groups (10, 100, and 500 ng/ml) and control group (P < 0.05) (Fig. 1) . These results indicated that rhSDF-1α can promote the migration of EPCs in a dose-dependent manner.
rhSDF-1α promotes the mobilization of endothelial-like cells in peripheral blood
To examine whether rhSDF-1α could mobilize EPCs into peripheral blood, the expressions of KDR, CD133, and CD34 were examined in cells by flow cytometry. Flow cytometry analysis indicated that the number of endothelial-like cells with KDR marker was increased in peripheral blood after rhSDF-1α stimulation. Flow cytometry results showed that endothelial-lineage cells with KDR marker were 2.5 ± 0.4, 24.4 ± 2.3, 8.6 ± 1.3, 3.3 ± 0.4, and 3.6 ± 0.5 cells per 10 4 cells in peripheral blood at 0, 4, 8, 12, and 24 h after intravenous injection of rhSDF-1α (Fig. 2) . The KDR level was elevated at 4 and 8 h (P < 0.05). The KDR expression reached its maximum in~4 h after administration (P < 0.05). The cells with CD133 and CD34 markers were not detected due to nonspecific antibodies for rabbit CD133 and CD34. The results showed that rhSDF-1α could mobilize endotheliallike cells into peripheral blood, thus increase the level of progenitor cells with endothelial lineage.
FD facilitates the parent artery reconstruction
To observe the effectiveness of FD in the treatment of saccular aneurysm, angiography was performed to observe the artery reconstruction at 2 weeks. Twenty-three FDs (17 stents, 3.0 mm × 15 mm; 6 stents, 4.0 mm × 20 mm) were successfully implanted into saccular aneurysm rabbits. Two weeks after stent implantation, follow-up angiography showed partial aneurysm occlusion in one rabbit of each group, parent artery occlusion in one rabbit of control group and complete aneurysm occlusion in 17 rabbits (9, rhSDF-1α group; 8, control group) (Fig. 3) . One rabbit of the rhSDF-1α group died due to diarrhea 15 days after stent implantation. These data showed that it is feasible to treat saccular aneurysm with FD with high occlusion rate.
rhSDF-1α enhances the expression of endothelial markers in neointima
To observe whether rhSDF-1α promoted reendothelialization in the aneurysm neck of saccular aneurysm after FD treatment, endothelial makers were examined within the neointima at the aneurysm neck. Four weeks after FD implantation, neointima at the aneurysm neck was collected for analyzing the expressions of endothelial markers. The RT-PCR results showed higher expression levels of Tie-2, KDR, VEcadherin, and E-selectin in rhSDF-1α group (P < 0.05). The relative levels of CD34, VE-cadherin, Tie-2, KDR, and E-selectin reached 0.43, 0.14, 0.20, 0.03, and 0.45 in the rhSDF-1α group and 0.44, 0.09, 0.17, 0.01, and 0.13 in the control group. However, there was no significant difference in the expression level of CD34 between the rhSDF-1α group and control group (P > 0.05) (Fig. 4) . These data indicated that the levels of the endothelial markers within the neointima at the aneurysm neck were increased after rhSDF-1α administration.
rhSDF-1α does not affect the neointima thickness at aneurysm neck
To examine whether rhSDF-1α promotes neointima growth, neointima thickness was measured. Two and 4 weeks after FD treatment, aneurysm was harvested and split into two parts. The struts embedded in the aneurysm neck were carefully drawn out under a microscope. After hematoxylineosin staining, neointima thickness was measured under the microscope. Two weeks later, the neointima thickness in the rhSDF-1α group and control group reached 0.012 ± 0.003 and 0.014 ± 0.004 mm, respectively (P > 0.05). Four weeks later, the neointima thickness in the rhSDF-1α group reached 0.035 ± 0.005 and 0.037 ± 0.006 mm, respectively (P > 0.05). No significant difference of intima thickness was observed between the rhSDF-1α and control groups. These data showed that rhSDF-1α did not promote neointima growth after rhSDF-1α administration.
rhSDF-1α accelerates the proliferation of endotheliallike cells at the aneurysm neck
To further investigate whether rhSDF-1α promotes reendothelialization process, we examined if endothelial-like cells existed at the (E,F) HE staining shows that the intima was formed on the stent struts at 2 weeks (E) and become thicker at 4 weeks (F). rhSDF-1α facilitates aneurysm reendothelialization after FD treatment aneurysm neck with scanning electron microscopy after rhSDF-1α administration. Two and 4 weeks after FD implantation, aneurysm neck was covered by thin neointima. Scanning electron microscopy showed more endothelial-like cells in aneurysm in the rhSDF-1α group than in the control group at 2 weeks (55 vs 13 cells/highpower field, P < 0.01) and 4 weeks (104 vs 60 cells/high-power field, P < 0.01) (Fig. 5) . The increased endothelial-like cells at the aneurysm neck after rhSDF-1α administration indicated that rhSDF-1α could promote reendothelialization at the aneurysm neck.
Discussion
Intracranial aneurysm is a common condition. Once ruptured, it will cause severe consequences. FD can alter aneurysm hydrodynamics, reconstruct parent artery, and provide scaffold for neointima formation at the aneurysm neck. Both hemodynamic experiments and clinical investigation showed its advantage for large and giant intracranial aneurysms [18] [19] [20] [21] . After FD implantation, long-term dual antiplatelet therapy is required, thus potentially enhancing the risk of bleeding complication. Early reendothelialization at the aneurysm neck is believed to reduce bleeding risk, since it can restore the biological vascular healing [22, 23] . In this study, we demonstrated the therapeutic effect of rhSDF-1α on aneurysm neck reendothelialization in saccular aneurysm after FD treatment. Endothelial markers expression was enhanced and more endothelial-like cells were observed at the aneurysm neck after rhSDF-1α administration. It has been known that SDF-1 plays a pivotal role in attracting stem cells through coupling with its ligand CXCR4 expressed on some stem cells [24] [25] [26] [27] . SDF-1 is also proved to promote vascular remodeling via recruiting smooth muscle progenitor cells [15] via SDF-1/CXCR4 signaling [16] . A previous study revealed that rhSDF-1α could facilitate reendothelialization after drug-eluting stent implantation in aorta abdominalis [17] .
In the current study, the deployed stents were different from that of Zhang et al. [17] . They used drug-eluting stent with low mesh coverage while we used FD with high mesh coverage. Disparities between these stents influenced endothelial regrowth and recovery [28] . The sites for stents deployment were also different. In our study, FD stents were deployed to cover the aneurysm neck and the neointima was directly formed on FD struts. In their study, however, drug-eluting stents were deployed in the aorta abdominalis. The underlined tissue substrate for stent was the medial layer instead of aneurysmal thrombosis. The interaction between fibroblast cells and smooth muscle cells with endothelial layer influences the vascular structural remodeling [29] . Perivascular stem cells resided in the adventitial layer also contribute to tissue repair [30, 31] . Therefore, the environments for endothelial regrowth were different. Without the support of underlying substrate, the mechanism of neointima regrowth differs, thus probably resulting in no difference of neointima thickness at the aneurysm neck between the two groups in our study. Notably, neointima thickness was influenced by multiple factors, including stent size and wall apposition [32] . In the present study, Figure 4 . Expression of endothelial markers in the aneurysm neck of saccular aneurysm detected by RT-PCR The mRNA levels of VE-cadherin, Tie-2, KDR, and E-selectin were elevated at 4 weeks after FD treatment. *P < 0.05, **P < 0.01. Figure 5 . Scanning electron microscopy of reendothelialization at the aneurysm neck rhSDF-1α accelerates reendothelialization at the aneurysm neck after FD treatment. At 2 and 4 weeks after FD treatment, more endothelial-like cells were observed at the aneurysm neck after rhSDF-1α administration. The right bar graph showed significantly more endothelial cells at the aneurysm neck in the rhSDF-1α group than that in control group. **P < 0.01. rhSDF-1α facilitates aneurysm reendothelialization after FD treatment we did not take these factors into consideration. However, both studies supported the therapeutic role of rhSDF-1α for accelerating reendothelialization.
The underlying mechanism for reendothelialization at the aneurysm neck after FD treatment remains elusive. In the present study, we noticed that more endothelial-like cells appeared at the aneurysm neck after rhSDF-1α administration and significantly enhanced gene expression of endothelial markers were observed, except CD34 that is a progenitor cells marker. On the contrary, the KDR positive cells were mobilized rapidly after rhSDF-1α stimulation in peripheral blood. We postulate that those mobilized cells homing to the aneurysm neck after rhSDF-1α stimulation have already been differentiated into specific cells and lose their CD34 marker in different environment at 4 weeks after FD implantation. We also postulate that the detected CD34 marker is expressed in situ progenitor cells in vascular structure. Due to the lack of specific antibody for rabbits, protein expression related to endothelial markers at the aneurysm neck was not validated in the present study. Increasing evidence supports that EPCs participate in vascular repair [33] [34] [35] . Kadirvel et al. [36] observed no EPCs in the newly formed intima on the FD struts and noticed some cells on struts in the periphery of the aneurysm neck probably migrated or originated from the parent artery. Meanwhile, the stem or progenitor cells can also be transformed into smooth muscle cells or endothelial cells due to transdifferentiation mechanism [37] [38] [39] . We postulate that multiple mechanisms may be involved in the reendothelialization process. The origin of these endothelial cells at the aneurysm neck needs further investigation. Multiple approaches have been used to mobilize stem cells from BM into the blood circulation, including application of CXCR4 ligand inhibitors and growth factors [40, 41] . AMD3100, a CXCR4 inhibitor, disrupts the interaction between SDF-1 and CXCR4 to mobilize stem cells [42] . For this reason, we did not use AMD3100 as an antagonist to validate whether SDF-1α plays its role through SDF-1α/CXCR4 signaling. Further study is needed to investigate the efficacy of CXCR4 inhibitors in reendothelialization. Although the role of SDF-1α in accelerating reendothelialization was demonstrated in the present study, its allergic reaction and toxicity should be tested in the future.
In conclusion, consecutive administration of rhSDF-1α can accelerate endothelial-like cells expansion at the aneurysm neck in elastase-induced saccular aneurysm rabbits after FD treatment. This study provides a potential therapeutic approach for endothelial restoration and reendothelialization.
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